Plasma pharmacokinetics of daptomycin in critically ill patients with renal failure and undergoing CVVHD

International Journal of Clinical Pharmacology and Therapeutics

Volumn 49, Issue 11, 2011, Pages 656-665

  Khadzhynov, D ^a   Slowinski, T ^a   Lieker, I ^a   Spies, C ^a   Puhlmann, B ^a   Konig T ^a   Uhrig, A ^a   Eggers, K ^a   Neumayer, H H ^a   Traunmuller F ^b,c,d   Joukhadar, C ^b,c,d   Peters, H ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b J & P Medical Research Ltd   (Austria)

^c HARVARD MEDICAL SCHOOL   (United States)

^d MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

Daptomycin; Pharmacokinetics; Renal failure; Renal replacement therapy

Indexed keywords

DAPTOMYCIN;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CONTINUOUS HEMODIALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; CRITICALLY ILL PATIENT; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; KIDNEY FAILURE; KIDNEY FUNCTION; LOADING DRUG DOSE; MALE; RECOMMENDED DRUG DOSE; SIDE EFFECT; SINGLE DRUG DOSE; STEADY STATE; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION;

AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; CRITICAL ILLNESS; DAPTOMYCIN; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RENAL DIALYSIS; RENAL INSUFFICIENCY;

EID: 80054783635     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CP201626     Document Type: Article

References (23)

1. Bouman CS. Antimicrobial dosing strategies in critically ill patients with acute kidney injury and high-dose continuous veno-venous hemofiltration. Curr Opin Crit Care. 2008; 14: 654-659. doi:10.1097/MCC.0b013e32830f937c PubMed
2. Czock D, Markert C, Hartman B, Keller F. Pharmacokinetics and pharmacodynamics of antimicrobial drugs. Expert Opin Drug Metab Toxicol. 2009; 5: 475-487. doi:10.1517/17425250902913808 PubMed
3. Schetz M. Drug dosing in continuous renal replacement therapy: general rules. Curr Opin Crit Care. 2007; 13: 645-651. doi:10.1097/MCC.0b013e3282f0a3d3 PubMed (Pubitemid 350059527)
4. Uchino S, Kellum JA, Bellomo R, Doig GS, Morimatsu H, Morgera S, Schetz M, Tan I, Bouman C, Macedo E, Gibney N, Tolwani A, Ronco C, Beginning and Ending Supportive Therapy for the Kidney (BEST Kidney) Investigators. Acute renal failure in critically ill patients: a multinational, multicenter study. JAMA. 2005; 294: 813-818. doi:10.1001/jama.294.7.813 PubMed
5. Hair PI, Keam SJ. Daptomycin: a review of its use in the management of complicated skin and soft-tissue infections and Staphylococcus aureus bacteraemia. Drugs. 2007; 67: 1483-1512. doi:10.2165/00003495-200767100-00008 PubMed (Pubitemid 47028521)
6. Steenbergen JN, Alder J, Thorne GM, Tally FP. Daptomycin: a lipopeptide antibiotic for the treatment of serious Gram-positive infections. J Antimicrob Chemother. 2005; 55: 283-288. doi:10.1093/jac/dkh546 PubMed (Pubitemid 40425449)
7. Weis F, Beiras-Fernandez A, Schelling G. Daptomycin, a lipopeptide antibiotic in clinical practice. Curr Opin Investig Drugs. 2008; 9: 879-884. PubMed
8. Bubalo JS, Munar MY, Cherala G, Hayes-Lattin B, Maziarz R. Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever. Antimicrob Agents Chemother. 2009; 53: 428-434. doi:10.1128/AAC.00943-08 PubMed
9. Chakraborty A, Roy S, Loeffler J, Chaves RL. Comparison of the pharmacokinetics, safety and tolerability of daptomycin in healthy adult volunteers following intravenous administration by 30 min infusion or 2 min injection. J Antimicrob Chemother. 2009; 64: 151-158. doi:10.1093/jac/dkp155 PubMed
10. Dvorchik B, Arbeit RD, Chung J, Liu S, Knebel W, Kastrissios H. Population pharmacokinetics of daptomycin. Antimicrob Agents Chemother. 2004; 48: 2799-2807. doi:10.1128/AAC.48.8.2799-2807.2004 PubMed (Pubitemid 38989139)
11. Safdar N, Andes D, Craig WA. In vivo pharma-codynamic activity of daptomycin. Antimicrob Agents Chemother. 2004; 48: 63-68. doi:10.1128/AAC.48.1. 63-68.2004 PubMed
12. Sader HS, Jones RN. Antimicrobial susceptibility of Gram-positive bacteria isolated from US medical centers: results of the Daptomycin Surveillance Program (2007 - 2008). Diagn Microbiol Infect Dis. 2009; 65: 158-162. doi:10.1016/j.diag-microbio. 2009.06.016 PubMed
13. Salama NN, Segal JH, Churchwell MD, Patel JH, Gao L, Heung M, Mueller BA. Intradialytic ad ministration of daptomycin in end stage renal disease patients on hemodialysis. Clin J Am Soc Nephrol. 2009; 4: 1190-1194. doi:10.2215/CJN.01650309 PubMed
14. Kielstein JT, Eugbers C, Bode-Boeger SM, Martens-Lobenhoffer J, Haller H, Joukhadar C, Traunmüller F, Knitsch W, Hafer C, Burkhardt O. Dosing of daptomycin in intensive care unit patients with acute kidney injury undergoing extended dialysis - a pharmacokinetic study. Nephrol Dial Transplant. 2010; 25: 1537-1541. doi:10.1093/ndt/gfp704 PubMed
15. Morgera S, Schneider M, Slowinski T, Vargas-Hein O, Zuckermann-Becker H, Peters H, Kindgen-Milles D, Neumayer HH. A safe citrate anticoagulation protocol with variable treatment efficacy and excellent control of the acid-base status. Crit Care Med. 2009; 37: 2018-2024. doi:10.1097/CCM.0b013e3181a00a92 PubMed
16. Dvorchik BH, Brazier D, DeBruin MF, Arbeit RD. Daptomycin pharmacokinetics and safety following administration of escalating doses once daily to healthy subjects. Antimicrob Agents Chemother. 2003; 47: 1318-1323. doi:10.1128/AAC.47.4.1318-1323.2003 PubMed (Pubitemid 36368592)
17. Martens-Lobenhoffer J, Kielstein JT, Oye C, Bode-Böger SM. Validated high performance liquid chromatography-UV detection method for the determination of daptomycin in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 2008; 875: 546-550. doi:10.1016/j.jchromb.2008.09.019 PubMed
18. Vandecasteele SJ, Boelaert JR, De Vriese AS. Staphylococcus aureus infections in hemodialysis: what a nephrologist should know. Clin J Am Soc Nephrol. 2009; 4: 1388-1400. doi:10.2215/CJN.01590309 PubMed
19. Salama NN, Segal JH, Churchwell MD, Patel JH, Gao L, Heung M, Mueller BA. Single-dose daptomycin pharmacokinetics in chronic hemodialysis patients. Nephrol Dial Transplant. 2010; 25: 1279-1284. doi:10.1093/ndt/gfp655 PubMed
20. Vilay AM, Grio M, Depestel DD, Sowinski KM, Gao L, Heung M, Salama NN, Mueller BA. Daptomycin pharmacokinetics in critically ill patients receiving continuous venovenous hemodialysis. Crit Care Med. 2011; 39: 19-25. doi:10.1097/CCM.0b013e3181fa36fb PubMed
21. Rudiger A, Rentsch K, Maggiorini M, Corti N. Daptomycin pharmacokinetics in critically ill patients undergoing continuous renal replacement therapy. Crit Care Med. 2011; 39: 1243-1244, author reply 1244-1245. doi:10.1097/CCM. 0b013e31820f6d58 PubMed
22. Churchwell MD, Pasko DA, Mueller BA. Daptomycin clearance during modeled continuous renal replacement therapy. Blood Purif. 2006; 24: 548-554. doi:10.1159/000097078 PubMed (Pubitemid 46030098)
23. King EA, McCoy D, Desai S, Nyirenda T, Bicking K. Vancomycin-resistant enterococcal bacteraemia and daptomycin: are higher doses necessary? J Antimicrob Chemother, 2011; 66: 2112-2118.